Editas Medicine Inc at Wells Fargo Healthcare Conference Transcript
Great. Thanks everyone for being here. My name is Yanan Zhu, and I'm one of the biotech analysts here at Wells Fargo. It's our privilege to have Editas Medicine's management team with us for our fireside chat here today.
With me here are Gilmore O'Neill, Chief Executive Officer; and Baisong Mei, Chief Medical Officer. Thank you, Baisong. Thank you, Gilmore, for being here.
' -
Thank you very much for having us.
Thank you.
Questions & Answers
Great. So, I think -- if we could, let's dive right into EDIT-301 for sickle cell disease and the ongoing RUBY trial, if that's okay. Wondering, how many sites have been opened? How many patients have been enrolled? And how many have been dosed?
'
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
